Doctor's Bio
Mehmet Asim Bilen, MD, serves as Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Bilen joined the clinical staff at Grady’s Cancer Center as a practicing physician in July 2016. He is actively involved in clinical research and patient care in the area of genitourinary cancers. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Grady Clinical Research Committee. Dr. Bilen holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.
Board Certifications
American Board of Internal Medicine
Affiliations
Emory
Education & Training
- Medical School: Hacettepe University Medical School
- Internship: Baylor College of Medicine
- Residency: Baylor College of Medicine
Fellowships
University of Texas MD Anderson Cancer Center
Locations and Directions
Correll Pavilion
Phone: (404) 616-1000
Location:
80 Gilmer St. SE
Atlanta, GA 30303
Publications
- Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O
The oncologist. 2025;
PMID: 41056445 - Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS
Cancer medicine. 2025;14(19):e71284.
PMID: 41031719 - Phase 1 Study of Palbociclib with Cisplatin or Carboplatin in the Management of Patients with Advanced Pancreatic Cancer.
Alese OB, Harvey RD, Wu C, Hitron E, Collins H, Scott S, Steuer C, Bilen MA, Carthon BC, Switchenko JM, Ramalingam SS, Owonikoko TK
The oncologist. 2025;
PMID: 40973049 - Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS
European urology. 2025;
PMID: 40954009 - The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies.
Maughan BL, Dyrskjøt L, Grivas P, Alcaraz A, Antonarakis ES, Bilen MA, Bivalacqua T, Cooperberg MR, Cheng L, Gupta S
European urology. 2025;
PMID: 40829964 - Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes.
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patnaik A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES
Prostate cancer and prostatic diseases. 2025;
PMID: 40796671 - Impact of Treatment Patterns and Sequencing on Clinical and Economic Outcomes in Patients with Metastatic Urothelial Cancer: IMPACT UC II Study.
Bilen MA, Diessner B, White J, Murphy L, Nguyen A, Kirker M, Gharibian N, Morris V, Bhanegaonkar A
The oncologist. 2025;
PMID: 40795035 - Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches.
Saeed F, Berchuck JE, Bilen MA, Gandhi JS, Nazha B, Brown JT, Schuster DM, Jani AB, Yu J, Harik LR
Cancer. 2025;131(16):e70037.
PMID: 40782341 - Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study.
Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M
European urology focus. 2025;
PMID: 40738794 - Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A
Clinical cancer research : an official journal of the American Association for Cancer Research. 2025;31(18):3854-3863.
PMID: 40689871
PLANNING
PREPARING FOR YOUR VISIT
Whether you’re a patient or you’re visiting one, a little planning beforehand can make your visit to Grady easier and more comfortable. Here, you’ll find everything you need to prepare for your visit, including an appointment checklist, admissions information, dining options, and much more.